Rittha Lertkoonalak
Overview
Explore the profile of Rittha Lertkoonalak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liegeon G, Harrison L, Nechba A, Halue G, Banchongkit S, Nilmanat A, et al.
J Infect
. 2019 Aug;
79(5):454-461.
PMID: 31401085
Objectives: The risk of kidney dysfunction on the WHO recommended first line regimens containing tenofovir disoproxil fumarate (TDF) without protease inhibitors (PI) remains unclear in Asian patients, especially those with...
2.
Jourdain G, Le Coeur S, Ngo-Giang-Huong N, Traisathit P, Cressey T, Fregonese F, et al.
PLoS Med
. 2013 Aug;
10(8):e1001494.
PMID: 23940461
Background: Viral load (VL) is recommended for monitoring the response to highly active antiretroviral therapy (HAART) but is not routinely available in most low- and middle-income countries. The purpose of...
3.
Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-A-Gad P, Lertkoonalak R, Eiamsirikit N, et al.
PLoS One
. 2011 Dec;
6(11):e27427.
PMID: 22132100
Background: WHO recommends starting therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs), i.e. nevirapine or efavirenz, with lamivudine or emtricitabine, plus zidovudine or...